- National Guideline Centre
- Acknowledgements
- 1. Guideline summary
- 2. Introduction
- 3. Development of the guideline
- 4. Methods
- 5. Risk factors and risk assessment tools
- 6. Diagnostic tests
- 7. Severity risk tools
- 8. Surveillance for the early detection of hepatocellular carcinoma (HCC)
- 9. Surveillance for the detection of varices
- 10. Prophylaxis of variceal haemorrhage
- 11. Primary prevention of bacterial infections in cirrhosis and upper gastrointestinal bleeding
- 12. Transjugular intrahepatic portosystemic shunt (TIPS) versus large-volume paracentesis (LVP) for ascites
- 13. Primary prevention of spontaneous bacterial peritonitis (SBP) in people with cirrhosis and ascites
- 14. Volume replacers in hepatorenal syndrome
- 15. Management of an episode of acute hepatic encephalopathy
- 16. Reference list
- 17. Acronyms and abbreviations
- 18. Glossary
- Appendices A–H
- Appendix A. Scope
- Appendix B. Declarations of interest
- Appendix C. Clinical review protocols
- Appendix D. Health economic review protocol
- Appendix E. Clinical article selection
- Appendix F. Health economic article selection
- Appendix G. Literature search strategies
- Appendix H. Clinical evidence tables
- References
- Appendices I–Q
- Appendix I. Economic evidence tables
- Appendix J. GRADE tables
- Appendix K. Forest plots
- Appendix L. Excluded clinical studies
- Appendix M. Excluded health economic studies
- Appendix N. Cost-effectiveness analysis: diagnostic tests and surveillance strategies for cirrhosis
- Appendix O. Unit costs
- Appendix P. Research recommendations
- Appendix Q. NICE technical team
- References